Europe (WHO region) vs Korea: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Korea
100.0%
in 2024
Europe (WHO region) rank
2nd
Korea rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Korea
How they compare
Korea currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Korea's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 3 times across 13 shared years of data; in 2011 it was Europe (WHO region) ahead.
Europe (WHO region) ranks 2nd and Korea ranks 1st of 11 groups.
Europe (WHO region) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 61.5% | 55.5% | 6.0% | Europe (WHO region) |
| 2020s | 93.8% | 92.0% | 1.8% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Korea?
- Korea, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Korea?
- 10.0%, with Korea ahead.
- How many years of comparable data are there for Europe (WHO region) and Korea?
- 13 years are reported by both, from 2011 to 2024.
- How do Europe (WHO region) and Korea rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Korea ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.